Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP1LC3B | Q9GZQ8 | 9/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 4/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21821615 | 0.76 | MAP1LC3B (0.66) | MAP1LC3BHPGDTSHRRXFP1MEN1 | |
| SCHEMBL22111739 | 0.69 | HTR2C (0.35) | MAP1LC3B | |
| SCHEMBL21792641 | 0.68 | MAP1LC3B (0.40) | MAP1LC3BHPGDTSHRMEN1RAB9A | |
| SCHEMBL21795165 | 0.67 | MAP1LC3B (0.68) | MAP1LC3BHPGDTSHRRXFP1MEN1 | |
| SCHEMBL22111821 | 0.65 | HPGD (0.62) | MAP1LC3BHPGDCYP2C9CYP2C19 | |
| SCHEMBL19294268 | 0.65 | SLC18A3 (0.44) | MAP1LC3BRAB9ASLC18A3CYP3A4CYP2C9 | |
| SCHEMBL25553472 | 0.65 | SLC18A3 (0.44) | MAP1LC3BRAB9ASLC18A3CYP3A4CYP2C9 | |
| SCHEMBL20284994 | 0.65 | SLC18A3 (0.44) | MAP1LC3BRAB9ASLC18A3CYP3A4CYP2C9 | |
| SCHEMBL428432 | 0.65 | MAP1LC3B (0.55) | MAP1LC3BHPGDMEN1KMT2AMAOB | |
| SCHEMBL1779869 | 0.64 | MAP1LC3B (1.00) | MAP1LC3BHPGDTSHRRXFP1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11319303-B2 | Compound used as autophagy regulator, and preparation method therefor and uses thereof | Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) | 2022-05-03 | — | — | US | disclosed |
| US-20200190066-A1 | COMPOUND USED AS AUTOPHAGY REGULATOR, AND PREPARATION METHOD THEREFOR AND USES THEREOF | Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) | 2020-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11319303-B2 | Compound used as autophagy regulator, and preparation method therefor and uses thereof | ATG7, SQSTM1, BECN1 | MAP1LC3B 15/4885HPGD 3647/4885TSHR 4336/4885 |
| US-20200190066-A1 | COMPOUND USED AS AUTOPHAGY REGULATOR, AND PREPARATION METHOD THEREFOR AND USES THEREOF | ATG7, SQSTM1, BECN1 | MAP1LC3B 15/4885HPGD 3647/4885TSHR 4336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.